Greenwich LifeSciencesGLSI
GLSI
About: Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
Employees: 6
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
5% more funds holding
Funds holding: 39 [Q3] → 41 (+2) [Q4]
0.15% more ownership
Funds ownership: 8.69% [Q3] → 8.84% (+0.15%) [Q4]
21% less capital invested
Capital invested by funds: $16.4M [Q3] → $13.1M (-$3.37M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$38
221%
upside
Avg. target
$38
221%
upside
High target
$38
221%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 36% 1-year accuracy 58 / 162 met price target | 221%upside $38 | Buy Reiterated | 11 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label HLA data.
Neutral
GlobeNewsWire
1 month ago
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into Europe.
Neutral
GlobeNewsWire
1 month ago
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the activation of clinical sites in Poland.
Neutral
GlobeNewsWire
1 month ago
Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01
STAFFORD, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of new clinical sites in the US.
Neutral
GlobeNewsWire
1 month ago
Greenwich LifeSciences Provides Update on Commercial Manufacturing
STAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the commercial manufacturing of GP2.
Neutral
Business Wire
1 month ago
Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning the Company and its directors' and officers' possible violations of state laws. If you own Greenwich LifeSciences stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New Yo.
Neutral
GlobeNewsWire
1 month ago
Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01
STAFFORD, Texas, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of clinical sites in Germany.
Neutral
GlobeNewsWire
3 months ago
Greenwich LifeSciences Partners with GIM in Italy
STAFFORD, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced its partnership with clinical sites in Italy.
Neutral
GlobeNewsWire
3 months ago
Greenwich LifeSciences Provides Update on Corporate Events
STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on corporate events.
Neutral
GlobeNewsWire
7 months ago
Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain
STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update of the expansion of clinical sites into Spain.
Charts implemented using Lightweight Charts™